Global Markets Direct’s, 'Cellulite - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cellulite, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cellulite. Cellulite - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Cellulite. - A review of the Cellulite products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Cellulite pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Cellulite. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Cellulite pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Cellulite - Pipeline Review, H2 2013 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cellulite Overview 6 Therapeutics Development 7 Pipeline Products for Cellulite - Overview 7 Pipeline Products for Cellulite - Comparative Analysis 8 Cellulite - Therapeutics under Development by Companies 9 Cellulite - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Unknown Stage Products 12 Cellulite - Products under Development by Companies 13 Cellulite - Companies Involved in Therapeutics Development 14 Auxilium Pharmaceuticals, Inc. 14 Halozyme Therapeutics, Inc. 15 Helix BioMedix, Inc. 16 Kedem Pharmaceuticals Inc. 17 Easton Pharmaceuticals Inc. 18 Cellulite - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Assessment by Therapeutic Class 26 Drug Profiles 28 collagenase clostridium histolyticum - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 HTI-501 - Drug Profile 32 Product Description 32 Mechanism of Action 32 RandD Progress 32 POS-002 - Drug Profile 34 Product Description 34 Mechanism of Action 34 RandD Progress 34 HB-2032 - Drug Profile 35 Product Description 35 Mechanism of Action 35 RandD Progress 35 HB-2031 - Drug Profile 36 Product Description 36 Mechanism of Action 36 RandD Progress 36 EP-005 - Drug Profile 37 Product Description 37 Mechanism of Action 37 RandD Progress 37 Cellulite - Recent Pipeline Updates 38 Cellulite - Discontinued Products 48 Cellulite - Product Development Milestones 49 Featured News and Press Releases 49 Oct 23, 2013: Auxilium Pharmaceuticals Announces First Patient Dosed in Phase 2a Cellulite Study of Collegenase Clostridium Histolyticum 49 Oct 23, 2013: BioSpecifics Technologies Announces Initiation of Phase 2a Study of XIAFLEX for Treatment of Cellulite 50 Dec 13, 2012: Auxilium Pharma Announces Encouraging Top-line 30-day Data From Xiaflex Phase Ib Study In Cellulite 51 Jan 31, 2012: Interim Data From Phase I Study Of HTI-501 Support Commencement Of Phase II Portion Of Clinical Trial 52 Jan 26, 2012: Auxilium Announces First Cohort Of Patients Dosed In XIAFLEX Phase Ib Cellulite Study 52 Sep 28, 2011: Halozyme Begins Clinical Trial With HTI-501 In Women With Edematous Fibrosclerotic Panniculopathy 53 Aug 31, 2011: Auxilium And BioSpecifics Announce Plans To Develop Additional Indications Using XIAFLEX 54 May 19, 2008: Halozyme Therapeutics Presents Pre-Clinical Studies on Dermal Remodeling With HTI-501, a Lysosomal Proteinase 54 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 Primary Research 56 Expert Panel Validation 56 Contact Us 57 Disclaimer 57
List of Tables
Number of Products under Development for Cellulite, H2 2013 7 Number of Products under Development for Cellulite - Comparative Analysis, H2 2013 8 Number of Products under Development by Companies, H2 2013 9 Comparative Analysis by Clinical Stage Development, H2 2013 10 Comparative Analysis by Early Stage Development, H2 2013 11 Comparative Analysis by Unknown Stage Development, H2 2013 12 Products under Development by Companies, H2 2013 13 Cellulite - Pipeline by Auxilium Pharmaceuticals, Inc., H2 2013 14 Cellulite - Pipeline by Halozyme Therapeutics, Inc., H2 2013 15 Cellulite - Pipeline by Helix BioMedix, Inc., H2 2013 16 Cellulite - Pipeline by Kedem Pharmaceuticals Inc., H2 2013 17 Cellulite - Pipeline by Easton Pharmaceuticals Inc., H2 2013 18 Assessment by Monotherapy Products, H2 2013 19 Number of Products by Stage and Target, H2 2013 20 Number of Products by Stage and Mechanism of Action, H2 2013 21 Number of Products by Stage and Route of Administration, H2 2013 23 Number of Products by Stage and Molecule Type, H2 2013 25 Number of Products by Stage and Therapeutic Class, H2 2013 27 Cellulite Therapeutics - Recent Pipeline Updates, H2 2013 38 Cellulite - Discontinued Products, H2 2013 48
List of Figures
Number of Products under Development for Cellulite, H2 2013 7 Number of Products under Development for Cellulite - Comparative Analysis, H2 2013 8 Number of Products under Development by Companies, H2 2013 9 Assessment by Monotherapy Products, H2 2013 19 Number of Products by Top 10 Route of Administration, H2 2013 22 Number of Products by Stage and Top 10 Route of Administration, H2 2013 23 Number of Products by Top 10 Molecule Type, H2 2013 24 Number of Products by Stage and Top 10 Molecule Type, H2 2013 25 Number of Products by Top 10 Therapeutic Class, H2 2013 26 Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 27
Auxilium Pharmaceuticals, Inc. Halozyme Therapeutics, Inc. Helix BioMedix, Inc. Kedem Pharmaceuticals Inc. Easton Pharmaceuticals Inc.